Yang Zhao, PhD

Executive Director, HEOR
Axsome Therapeutics, Inc.

Poster(s):

• (134) Budget impact of Symbravo® (MoSEIC™ meloxicam and rizatriptan) to health plans in the United States for the acute treatment of migraine in adults
  Wednesday, October 29, 2025

• (362) Real-world characteristics and treatment patterns of patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets, cariprazine, brexpiprazole, or esketamine
  Wednesday, October 29, 2025

• (364) Real-world healthcare utilization and costs associated with using dextromethorphan-bupropion extended-release tablets versus branded comparators for the treatment of major depressive disorder
  Wednesday, October 29, 2025

• (366) Healthcare costs for patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets as a first or subsequent line of treatment
  Wednesday, October 29, 2025